Phase III ocriplasmin data published as regulatory decisions loom
This article was originally published in Scrip
While they await regulatory decisions in the US and EU for the ophthalmic injection ocriplasmin, Thrombogenics and its partner Alcon, a division of Novartis, published results from two Phase III studies for what could be the first approved treatment for vitreomacular adhesion (VMA) in New England Journal of Medicine (16 August).
You may also be interested in...
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.